Genome-wide association studies of Systemic Lupus Erythematosus (SLE) nominate 3,073 genetic variants at 91 risk loci. To systematically screen these variants for allelic transcriptional enhancer activity, we constructed a massively parallel reporter assay (MPRA) library comprising 12,396 DNA oligonucleotides containing the genomic context around every allele of each SLE variant. Transfection into EBV-infected B cells revealed 482 variants with enhancer activity, with 51 variants showing genotype-dependent (allelic) enhancer activity at 27 risk loci. In-depth analysis of allelic transcription factor (TF) binding at and around these 51 variants identified one class of TFs whose DNA-binding motif tends to be directly altered by the risk variant and a second, larger class of TFs that also bind allelically but do not have their motifs directly altered by the variant. Collectively, our approach provides a blueprint for the discovery of allelic gene regulation at risk loci for any disease and offers insight into the transcriptional regulatory mechanisms underlying SLE.
Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect multiple organs, leading to debilitating inflammation and mortality 1 . Up to 150 cases are found per 100,000 individuals, and the limited treatment options contribute to considerable economic and social burden 1, 2 . Epidemiological studies have established a role for both genetic and environmental factors in the development of SLE 2 . SLE has a relatively high heritability 3 . The vast majority of patients do not have a single disease-causing mutation (such as mutations in complement protein 1q); instead, genetic risk is accumulated additively through many genetic risk loci with modest effect sizes 4 .
Genome-wide association studies (GWASs) have identified 91 genetic risk loci that increase disease risk of SLE in a largely additive fashion 4 . Each SLE risk locus is a segment of the genome containing a polymorphic "tag" variant (i.e., the variant with the most significant GWAS p-value) and the genetic variants in linkage disequilibrium with the tag variant. The majority (68%) of the established SLE risk loci do not contain a disease associated coding variant that changes amino acid usage 5 . Instead, variants at these loci are found in non-coding regions of the genome such as introns, promoters, enhancers, and other intergenic areas. Enrichment of these variants in enhancers and at transcription factor (TF) binding sites 6, 7 implies that transcriptional perturbation may be a key to the development of SLE 8 . However, given the large number of candidate variants identified by GWAS, identification of the particular causal variant(s) remains challenging.
SLE is a complex disease that involves multiple cell types 2 . Previous systematic studies demonstrate that SLE risk loci are enriched for B cell specific genes 9 and regulatory regions 10 .
Established biological mechanisms further highlight a key role for B cells in SLE -as the autoantibody-secreting cell type, B cells are critical to the pathoetiology of SLE, a disease characterized by autoantibody production 11 . B cells also present self-antigens to T cells in the development of an autoantigen-focused (i.e., "self") inflammatory response 12 . Meanwhile, Epstein-Barr virus (EBV)-infected B cells have been implicated in SLE, with patients having a greater number of EBV-infected B cells and a higher viral load than people without SLE 13, 14 . In addition, EBV infection is significantly more prevalent in SLE cases than controls 15, 16 , and EBNA2 genomic interactions are concentrated at SLE risk loci in EBV-infected B cells 10 . Accordingly, EBV-infected B cells offer an ideal disease-relevant model for studying the effects of SLE risk variants at many SLE risk loci.
To systematically identify the SLE genetic risk variants that contribute to transcriptional dysregulation in EBV-infected B cells, we designed and applied a massively parallel reporter assay (MPRA) 17, 18 (Figure 1) . MPRA extends standard reporter assays, replacing low-throughput luciferase with high-throughput RNA expression detection. In this study, we used MPRA to simultaneously screen the full set of genome-wide significant SLE-associated genetic variants for effects on gene regulation. Using this experimental approach, we nominate 51 putative causal variants that result in genotype-dependent (allelic) transcriptional regulation. Integration of these data with TF binding site predictions and functional genomics data reveals two distinct mechanisms whereby TFs bind risk variants in an allelic manner -directly impacted by a given variant (i.e., the variant directly alters the TF's DNA-binding site) or indirectly impacted by the variant (i.e., the variant alters the DNA binding of the TF's physical interaction partner or modulates chromatin accessibility). Collectively, these results reveal an important role for groups of TFs in the mediation of allelic enhancer activity at plausibly causal SLE risk variants in EBVinfected B cells.
Results

MPRA library design and quality control
We first collected all SLE-associated risk loci reaching genome-wide association significance (p<5x10 -8 ) published through March 2018 (Supplemental Data Set 1). Studies of all ancestral groups were included, and independent risk loci were defined as loci with lead (tag) variant at r 2 <0.2. For each of these 91 risk loci, we performed linkage disequilibrium (LD) expansion (r 2 >0. 8) in each ancestry of the initial genetic association(s), to include all possible disease-relevant variants (Supplemental Data Set 2). In total, this procedure identified 3,073 genetic variants. All established alleles of these variants were included, with 36 variants having three or more alleles.
We also included 20 additional genetic variants from a previously published study 18 as positive and negative controls to assess the library's performance (Supplemental Data Set 3).
For each variant, we generated a pair of 170 base pair (bp) DNA oligonucleotides (subsequently referred to as "oligos") for each allele, with the variant located in the center and identical flanking genomic sequence across the alleles (Supplemental Data Set 4). A total of 12,478 oligos (3,093 variants with 6,239 alleles) were synthesized. For barcoding, the oligos were ligated to a pool of random 20mers. Each uniquely ligated barcode was matched with perfectly synthesized oligos.
The number of unique barcodes per oligo had an approximately normal distribution with a median of 729 barcodes per oligo (Supplemental Figure 1A , Supplemental Data Set 5). Only oligos with at least 30 unique barcodes were used for downstream analyses. A fragment containing a minimal promoter and an eGFP gene was inserted between the oligo and barcode to generate the MPRA transfection library. We note that the use of a minimal promoter allows us to measure the ability of alleles to enhance, but not reduce, transcriptional activity. Three aliquots of the library were independently transfected into the EBV-infected B cells GM12878. We then used nucleic acid capture to enrich for eGFP mRNA and sequenced the barcode region. The normalized barcode ratio between the eGFP mRNA and the plasmid DNA was used to quantify the amount of enhancer activity driven by each oligo. This mRNA to DNA ratio measures the enhancing effect of an allele on eGFP expression under the control of a minimal promoter ( Figure 1 ). We observed strong correlation of enhancer activity between experimental replicates (mean pairwise Pearson correlation of 0.99) (Supplemental Figure 1B, C, D) . Likewise, calibration variants showed high accuracy, with 17 of the 20 variants matching the results of a previous study 18 (87.5% sensitivity and 75% specificity), collectively demonstrating a robust experimental system (Supplemental Data Set 3).
Hundreds of SLE risk variants are located in genomic regions with enhancer activity in
EBV-infected B cells
Using the SLE MPRA library, we next identified genetic variants capable of driving enhancer activity in EBV-infected B cells GM12878. An SLE risk variant was considered to reside within a region with enhancer activity if an oligo corresponding to any allele had significantly increased transcriptional regulatory activity compared to controls (see Methods). Not all statistically significant changes in transcriptional activity are necessarily biologically relevant -a highly consistent, but slight change in expression levels is statistically, but not biologically, meaningful.
We therefore considered an oligo to have enhancer activity only when (1) the oligo had statistically significant enhancer activity (pFDR<0.05) and (2) we observed at least a 50% increase in transcriptional activity compared to the corresponding barcode counts in the plasmid control.
Based on these criteria, 16% of SLE risk variants (482 variants, 853 alleles) demonstrated enhancer activity, henceforth referred to as "enhancer variants" (enVars) and "enhancer alleles" (enAlleles), respectively (Figure 2A , Supplemental Data Set 6).
We next explored the potential effects of enVars on gene expression. We connected each enVar to one or more genes using an approach that takes into account chromatin looping interactions, Next, we searched for functional genomic features enriched within enVars relative to non-enVars using the RELI algorithm 10 . In brief, RELI estimates the significance of the intersection between an input set of genomic regions (e.g., enVars) and each member of a collection of functional genomics datasets (e.g., ChIP-seq (Chromatin immunoprecipitation with sequencing) for a particular histone mark or TF). For this analysis, we identified, curated, and systematically processed the 571 GM12878 ChIP-seq datasets available in the NCBI Gene Expression Omnibus We next asked if the genomic binding sites of particular TFs in B cells were enriched within our enVars using RELI and the anti-TF ChIP-seq datasets from GM12878. As expected, the enVars are highly enriched for ChIP-seq signal of TFs involved in regulation of the immune response 19-21 , relative to variants lacking enhancer activity (Figure 2C , Supplemental Data Set 9). In particular, we found significant enrichment for all members of the NFkB TF family: REL/C-Rel (6.4-fold, pcorrected <10 -26 ), NFKB1/p50 (3.0-fold, pcorrected <10 -18 ), RELA/p65 (3.1-fold, pcorrected <10 -16 ), RELB (2.7-fold, pcorrected <10 -10 ), and NFKB2/p52 (2.2-fold, pcorrected <10 -7 ). These results are consistent with our previous findings that altered binding of NFkB TFs is likely an important mechanism conferring SLE risk 10 . We also found significant enrichment for other TFs that have been previously implicated in SLE pathogenesis, such as PAX5 22 , MED1 23 , IKZF1 24 , ELF1 25 and the EBV-encoded EBNA2 transactivator 10 (Figure 2C , Supplemental Data Set 9). As a complementary approach, we next assessed enrichment for TF binding site motifs in the enAllele DNA sequences using HOMER 26 and motifs contained in the Cis-BP database 27 (see Methods) .
This analysis also revealed enrichment of multiple TF families with known roles in SLE, including ETS, NFkB, and IRF 3 (Figure 2D , Supplemental Data Set 10). Many of these same TFs also have enriched ChIP-seq peaks at SLE risk loci 10 . Collectively, these results indicate that particular TFs tend to not only concentrate at SLE risk loci 10 , but also concentrate at alleles capable of driving gene expression in EBV-infected B cells.
MPRA identifies 51 SLE risk variants with allelic enhancer activity in EBV-infected B cells
We next used our MPRA library to identify SLE genetic risk variants that drive allele-dependent (allelic) enhancer activity. Allelic activity was assessed for each enVar by comparing enhancer activity between each pairs of alleles. We considered a SLE variant allelic if (1) at least one of its alleles is an enAllele; (2) we observed significant genotype-dependent activity using Student's t- Three of the allelic enVars can also alter the amino acid sequence of proteins -rs1059702 (IRAK1), rs1804182 (PLAT), and rs3027878 (HCFC1), consistent with previous studies identifying dual-use codons in the human genome 28 . Collectively, these 51 variants represent causal variant candidates for 27 SLE risk loci (30% of all tested loci) (Supplemental Data Set 12). For these 27 risk loci, our approach reduced the number of potential causal variants in EBV-infected B cells from an average of 84 variants to an average of two variants per risk locus (Figure 3B ). For example, at 17q12 (marked by rs8079075), we reduce the candidate causal variant set from 249 to one, with the rs112569955 "G" risk allele showing a 36% increase in enhancer activity compared to the "A" non-risk allele.
Particular TFs have altered binding at SLE loci with allelic enhancer activity
To identify candidate regulatory proteins that might participate in allelic SLE mechanisms, we next used RELI to identify GM12878 ChIP-seq datasets that significantly overlap allelic enVars . Also consistent with our previous study 10 , we observe strong enrichment for the EBV-encoded EBNA2 protein (7 of 51 allelic enVars, 17.7-fold enriched, pcorrected <10 -19 ).
Collectively, these data reveal particular regulatory proteins that might participate in the mechanisms contributing to SLE at multiple risk loci by driving allelic enhancer activity.
We next used the MARIO pipeline 10 to search for allelic binding events (i.e., allelic imbalance between sequencing read counts) at SLE variants within the 571 GM12878 ChIP-seq datasets.
By necessity, this approach is limited to the 13 allelic enVars that are heterozygous in GM12878.
In total, this procedure identified four variants with strong allelic imbalance (MARIO ARS value > 0.4) in at least one ChIP-seq dataset (Supplemental Data Set 14), revealing groups of TFs and transcriptional regulators that allelically bind SLE risk variants with genotype-dependent MPRA enhancer activity. For example, the rs3101018 variant, which is associated with SLE 30 and rheumatoid arthritis 31 in Europeans, shows 1.7-fold stronger enhancer activity for the reference/non-risk 'C' allele compared to the non-reference/risk 'T' allele ( Figure 4A) . These results are consistent with a previously established eQTL obtained from GTEx 32 , which demonstrates higher Complement C4A (C4A) expression in EBV-infected B cells for the rs3101018 'C' allele than the 'T' allele ( Figure 4B ). Our MARIO allelic ChIP-seq analysis reveals 11 regulatory proteins that prefer the 'C' allele and 2 that prefer the 'T' allele ( Figure 4C ). Among these, particularly robust signal is obtained for ATF7, with one experiment displaying 77 vs. 18
reads ('C' vs. 'T') and another showing 66 vs. 23 reads ('C' vs. 'T') (Supplemental Data Set 14).
Moreover, CREB1 and CREM strongly favor the 'C' allele as well (Supplemental Data Set 14).
In agreement with these data, computational analysis of the DNA sequences surrounding this variant predicts that ATF7, CREB1, and CREM will all bind more strongly to the 'C' than the 'T' allele ( Figure 4D) . Intriguingly, seven additional proteins (FOXK2, PKNOX1, ARID3A, ZNF217, ARNT, MEF2B, and FOXM1) also bind allelically and have known DNA binding motifs 33 , but none of them have binding sites altered by the variant. Further, we do not observe allelic chromatin accessibility in available ATAC-seq datasets (9 vs. 7 reads). Together, these results reveal a potentially causative SLE regulatory mechanism involving weaker direct binding of ATF7/CREB/CREM to the 'T' risk allele, altering the recruitment of additional proteins to the locus and lowering the expression of C4A.
We observe a similar phenomenon for the rs2069235 variant, which is associated with SLE in Asian ancestries 34 and rheumatoid arthritis in Europeans 35 . rs2069235 displays much stronger enhancer activity for the 'A' (non-reference/risk) allele compared to the 'G' (reference/non-risk) allele (Figure 4E) , consistent with the established synaptogyrin 1 (SYNGR1) eQTL in EBVinfected B cells 32 (Figure 4F) . Inspection of our allelic ChIP-seq data reveals a larger number of proteins binding to the 'A' than the 'G' allele (14 vs. 2) ( Figure 4G ). Among these 16 proteins, only IKZF2 and ELF1 have their binding sites directly altered by the variant (Figure 4H ). Together, these data are consistent with a potentially causative SLE molecular mechanism involving stronger direct binding of IKZF2 to the 'G' non-risk allele and stronger ELF1 binding to the 'A' risk allele, along with indirectly altered binding of multiple TFs to this locus.
Genotype-dependent binding to SLE variants with allelic activity by variant overlapping and variant adjacent TFs
As illustrated by the above examples, a particular TF can be involved in allelic mechanisms that are either directly impacted by a given variant (i.e., the variant directly alters the TF's DNA-binding site) or indirectly impacted by the variant (i.e., the variant alters the DNA binding of the TF's physical interaction partner, modulates chromatin accessibility, or affects another mechanism). At a given locus, we designate such TFs as variant overlapping and variant adjacent TFs, respectively ( Figure 5A) . We next sought to discover such TFs at the 51 allelic enVars. At each allelic enVar locus, we identified variant overlapping TFs as those TFs predicted to have strong binding to one allele and weak binding to the other allele. Likewise, we identified variant adjacent TFs as those TFs with proximal strong predicted binding sites that do not directly overlap the variant (see Methods). We then searched for particular TFs that tend to act as variant overlapping TFs or as variant adjacent TFs at the 51 allelic eVars using a proportion test (see Methods) and confirmed that their binding site locations are distributed relative to the variant as expected ( Figure 5B) . Consistent with our results at the C4A and SYNGR1 loci, variant overlapping TFs include members of the ETS (e.g., ELF1) and ATF-like (e.g., ATF7) families, along with other TFs whose genetic loci are associated with SLE, including IRF5 36 (Figure 5C , Supplemental Data Set 15). Variant adjacent TFs represent a largely distinct class, but also include several TFs with SLE genetic associations, including NFkB 37 , the Ikaros (IKZF) family 38 , and HMGA family members 39 (Figure 5D , Supplemental Data Set 15). Collectively, these analyses reveal two distinct classes of TFs at a given SLE-associated locus that both likely play key roles in SLE mechanisms, along with particular TFs that tend to participate in one class or the other.
In summary, through the application of an allelic MPRA library to the EBV-infected B cells GM12878, we identified global transcriptional enhancer activity at 16% of SLE-associated genetic variants (enVars), with particular transcriptional regulatory proteins concentrated at these genomic locations. We further identified 51 SLE risk variants with allelic enhancer activity (allelic enVars) that we now nominate as plausibly causal by acting through genotype-dependent changes in enhancer activity in EBV-infected B cells. Using experimental TF ChIP-seq data and TF binding site motif scanning, we propose a model where the collective action of the genotypedependent binding of particular variant overlapping and variant adjacent TFs leads to genotypedependent transcriptional activity at SLE risk loci.
Discussion
Genome-wide association studies identify genetic loci with statistical disease associations.
However, each risk locus often contains many plausible variants due to linkage disequilibrium.
This study is the first direct genome-wide measurement of enhancer activity of the ~3000 known SLE genetic risk variants in any context. Unbiased experimental approaches such as MPRA are vital for resolving causal variants and their molecular mechanisms of action.
Our results indicate that 16% of the SLE risk variants examined in this study have enhancer activity in the EBV-infected B cells GM12878. Furthermore, 51 of these enhancer variants at 27 loci have allelic enhancer activity. These findings are consistent with the theory that a large proportion of the genetic risk of SLE is mediated through transcriptional perturbation of critical B cell genes. SLE risk loci that lack allelic enVars in GM12878 might act in other cell types (e.g., T cells) and/or under different conditions (e.g., subsequent to interferon stimulation).
A critical finding of this study is that SLE risk variants with allelic enhancer activity can alter the binding of many TFs. Although variants can directly affect the binding of variant overlapping TFs via disruption of a DNA-binding site, they can also simultaneously alter the binding of other variant adjacent TFs, presumably via genomic mechanisms such as altered chromatin accessibility, altered histone marks, indirect TF recruitment through physical interactions, changes in DNA shape, or changes to protein interaction partner DNA binding. In general, a given TF can be variant overlapping at one locus and variant adjacent at another, as exemplified by ATF7 ( Figure   4C , G). Nonetheless, particular TF families tend to act as variant overlapping TFs at SLE loci (such as Ets, E-box, and ATF), whereas others tend to act as variant adjacent TFs (such as HMGA, Hox, and NFkB). Notably, many of these variant overlapping and variant adjacent TFs are themselves encoded by genetic risk loci associated with SLE (e.g., IRF5 36 , NFkB 37 , and ETS1 40 ), suggesting that there are multiple means through which a particular TF can contribute to disease-based genetic mechanisms. For example, IRF5 targets might be mis-regulated in an SLE patient due to genetic associations in the promoter of IRF5 that result in altered IRF5 protein levels 36 , or by genetic variants located within or adjacent to IRF5 binding sites at other genomic loci. It is currently unknown if these TF attributes are shared with other human diseases.
This study reveals possible causal genetic mechanisms involving altered binding of particular TFs at two important SLE risk loci. C4A is a component of the inflammatory complement pathway that is critical for the appropriate clearance of apoptotic cells 41 . People without C4A due to rare, protein-changing mutations are at a greatly increased risk for autoimmune diseases, including type I diabetes and SLE 42 . Further, the risk of developing SLE is 2.62 times higher in subjects with low total C4A 41 . Consistent with this observation, the SLE risk allele at this genetic locus identified in our MPRA is associated with lower C4A expression ( Figure 4B) . Additionally, the SLE risk locus encoding SYNGR1 was recently identified in a high-density genotyping study of subjects with Asian ancestry 34 and also increases disease risk for schizophrenia 43 , primary biliary cirrhosis 44 , and rheumatoid arthritis 45 . SYNGR1 is an integral membrane protein that is most robustly expressed in neurons of the central nervous system; however, there is measurable transcription and translation of SYNGR1 in other tissues, including developing B cells 46 In this study, we used MPRA to uncover specific genetic variants within the risk haplotypes of a complex disease in a specific cell type. Our integrative analyses reveal specific molecular mechanisms underlying genotype-dependent transcriptional regulation and SLE disease risk. We conclude that MRPA is a robust tool for the nomination of causal genetic risk variants for any phenotype or disease with risk loci that act through genotype-dependent gene regulatory mechanisms, with this study providing a blueprint for dissecting the genetic etiology of the many complex human diseases.
Online Methods
Variant selection and DNA sequence generation
All SLE-associated genetic risk loci reaching genome-wide significance published through March 2018 were included in this study 24, 30, 36, 40, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . A total of 91 genetic risk loci were used for linkage disequilibrium (LD) expansion (r 2 >0.8) based on 1000 Genomes Data 57 in the ancestry(ies) of the initial genetic association using PLINK 58 (Supplemental Data Set 1) . All expanded variants were updated to the dbSNP 151 table 59 from the UCSC table browser 60 based on either variant name or genomic location. Unmappable variants were discarded. We also included 20 genetic variants from the Tewhey et al. 18 
MPRA experiments
Library Assembly
For assembly of the MPRA library, we followed the procedure described by Tewhey et al. 18 of LB Broth buffer supplemented with 100 µg/mL of carbenicillin at 37 °C for 12 to 16 hrs. The plasmid was then extracted using the QIAGEN Endo-free Plasmid Giga Kit.
Oligo and barcode association
The oligo and barcode regions were amplified from the backbone library through 4X PCR with a 100 µL system containing 200 ng plasmid, 50 µL NEBNext® Ultra™ II Q5® Master Mix, 0.5 µM TruSeq_Universal_Adapter_P5 and MPRA_v3_TruSeq_Amp2Sa_F_P7. PCR was performed under the following conditions: 95°C for 20 sec, 6 cycles of (95°C for 20 sec, 62°C for 15 sec, 72°C for 30 sec), 72°C for 2 mins. The product was then purified, and indices were added through a 100µl system containing all purified product, 50µl NEBNext® Ultra™ II Q5® Master Mix, 0.5 µM TruSeq_Universal_Adapter_P5 and index primer. PCR was performed as above, except for only 5 cycles. Samples were purified, molar pooled, and sequenced using 2x125bp on Illumina NextSeq 500.
Transfection
The GM12878 cell line was grown in RPMI medium supplemented with 10% FBS, 100 units/mL of penicillin, and 100 µg/mL of streptomycin. Cells were seeded at a density of 5 x 10 5 cells/mL the day before transfection. For triplicate transfections, we collected a total of 5 x 10 7 cells per replicate. Cells were then suspended with 50 µg transfection library plasmid in 400 µL Buffer R.
Electroporation was performed with the Neon transfection system in 100µl needles with 3 pulses of 1200V, 20 ms each. After transfection, cells were recovered in 50 mL pre-warmed RPMI medium supplemented only with 10% FBS for 24 hrs. Cells were then collected for preparation of the sequencing library for barcode counting.
Sequencing library for barcode counting
Total RNA of transfected cells was extracted by the RNeasy Midi Kit following the manufacturer's instruction. Extracted RNA was subjected to DNase treatment in a 375 µL system with 2.5 µL Turbo DNase and 37.5 µL Turbo DNase Buffer at 37°C for 1 hr. 3.75 µL 10% SDS and 37.5 µL 0.5M EDTA were added to stop DNase with 5 mins of incubation at 75°C. The whole volume was used for eGFP probe hybridization in an 1800 µL system, with 450 µl 20X SSC Buffer, 900 µL All primers used in this study are provided in Supplemental Table 1 .
MPRA data analysis
Oligo and barcode association
Paired-end, 125 bp reads were first quality filtered using Trimmomatic-0.38 61 were mapped back to the synthesized oligo sequences using Bowtie2 62 (flags: -X 250, --verysensitive, -p 16). Barcodes were then associated with the oligo sequences using the read ID. Only uniquely mapped barcodes were used for downstream analysis.
Barcode counting
Single end 75 bp reads were first quality filtered using Trimmomatic-0.38 61 the two bases directly adjacent to the barcode were kept. Barcodes were then associated with the retained reads using the read ID. Only barcodes that met our quality threshold requirements described above in the methods section "Oligo and barcode association" were used for downstream analysis.
Enhancer variant (EnVar) identification
We followed the procedures described in the "Identification of Regulatory Oligos" section of Tewhey et al. 18 18 to estimate accuracy, sensitivity, and specificity.
Allelic enVar identification
Only enVars were considered for allelic analysis. The barcode counts from every allele of each enVar were used for calculating p-values by comparing the log2 ratios of the non-reference allele vs the reference allele, normalized by plasmid controls, using Student's t-test 18 . P-values were adjusted with the Benjamini-Hochberg FDR-based procedure. A corrected p-value of less than 0.05 was required for significance. Only significant alleles with 25%-fold changes or greater were identified as allelic enVars. We have created an R package (mpraprofiler) for performing this analysis, which is available on the Weirauch lab GitHub page (https://github.com/WeirauchLab/).
Downstream MPRA analysis
Gene annotation
We annotated each SLE genetic variant with its nearest gene using the NCBI RefSeq table 65 downloaded from the UCSC table browser 60 . enVars were annotated using a combination of DNA looping interactions (GM12878 Capture Hi-C data 66, 67 ) and eQTL data obtained from EBVinfected B cell lines (GTEx Analysis V7 (dbGaP Accession phs000424.v7.p2) 32 and other individual studies [68] [69] [70] [71] ). For all variants, the target genes were annotated (Supplemental Data Set 2) using the union of promoter interacting genes and eQTL genes, when available. Otherwise, target genes were annotated as the nearest gene. Allelic enVars gene targets were classified into four tiers: a Tier 1) variant is both an eQTL and also loops to the promoter of the same gene; a Tier 2) variant has an eQTL for at least one gene; a Tier 3) variant only loops to the promoter of at least one gene; a Tier 4) variant is neither an eQTL nor loops to the promoter of any gene.
TF binding site motif enrichment analysis
To identify specific TFs whose binding might contribute to the enhancer activity observed in our MPRA experiments, we performed HOMER 26 TF binding site motif enrichment analysis.
Specifically, we used HOMER to calculate the enrichment of each motif in the sequence of enAlleles compared to the sequences of non-enAlleles. HOMER was modified to use the large library of human position weight matrix (PWM) binding site models contained in build 2.0 of the CisBP database 27 and a log base 2 log likelihood scoring system.
GO enrichment analysis
Enrichr 72,73 was used for GO enrichment analysis. In short, the target genes of enVars were passed to Enrichr for analysis. Results from the GO biological process (2018) category were used Set 8, Supplemental Figure 2 ).
Identification and processing of publicly available GM12878 ChIP-seq data
571 ChIP-seq datasets were obtained from the Gene Expression Omnibus (GEO) 74 and duplicate reads are removed using picard (v1.89) 79 . Finally, peaks are called using MACS2 (v2.1.2) (flags: callpeak -g hs -q 0.01 -f BAM) 80 . ENCODE blacklist regions 81 were removed from the peak sets using the hg19-blacklist.bed.gz file available at https://github.com/Boyle-Lab/Blacklist/tree/master/lists/Blacklist_v1. ChIP-seq datasets GSM1666207, GSM2748907 and GSM1599157 were removed due to the low number of cells used in the experiments.
Functional genomics dataset enrichment analysis with RELI
We used the RELI 10 algorithm to identify genomic features (TF binding events, histone marks, etc.) that coincide with enVars. As input, RELI takes the genomic coordinates of enVars. RELI then systematically intersects these coordinates with one of the GM12878 ChIP-seq datasets, and the number of input regions overlapping the peaks of this dataset (by at least one base) is counted. Next, a p-value describing the significance of this overlap is estimated using a simulation-based procedure. To this end, a 'negative set' is created for comparison to the input set, which in this study contains the set of non-enVars (i.e., variants with no allele having an We performed similar RELI analysis for allelic enVars. As input, we used the allelic enVar sites.
For the 'negative set', we used the set of common SNPs taken from the dbSNP142 database downloaded from the UCSC table browser 60 .
Identification of allelic ChIP-seq reads using MARIO
To identify possible mechanisms underlying our allelic enVars, we applied our MARIO 10 method to the GM12878 ChIP-seq dataset collection described above. In brief, MARIO identifies common genetic variants that are (1) heterozygous in the assayed cell line (here, GM12878) and (2) located within a peak in a given ChIP-seq dataset. It then examines the sequencing reads that map to each heterozygote in each peak for imbalance between the two alleles. Results are combined across experimental replicates to produce a robust Allelic Reproducibility Score (ARS).
Results with MARIO ARS values >0.4 were considered allelic, and any TF with inconsistent allelic imbalance across ChIP-seq datasets at a given variant site was removed, following our previous study 10 .
Identification of variant overlapping and variant adjacent TFs
Variant overlapping TFs were identified using an algorithm that compares predicted TF binding motif scores between the different alleles of each allelic enVar. First, we padded each allele of a given allelic enVar with 25 bps of upstream and downstream DNA sequence (a sufficient length to account for any known human TF binding sites 82 ). The algorithm consists of two major components: (1) individually scoring the two alleles of a given variant with a given TF model; and
(2) quantifying the difference in the binding intensity between these two alleles. DNA sequences are scored using the large collection of human TF position frequency matrix (PFM) models contained in the Cis-BP database 27 and the log-likelihood PFM scoring system 83 . Since loglikelihood score distributions vary substantially (depending on the information content of a given motif), we employ a simple scaled scoring system that maps a given log-likelihood score to the percentage of the maximum achievable log-likelihood score of the given motif -we refer to this value as the "relative PFM score". We identify binding site altering events (i.e., "creating" or "breaking" a predicted binding site for a given TF motif) as cases where one allele has a relative PFM score of 70% or higher, and the other allele has a score of less than 40%. For a given variant, any TF with allelic ChIP-seq sequencing reads (see above) and a binding site altering event for any of its motifs was deemed a variant overlapping TF. Any TF with allelic ChIP-seq sequencing reads and a lack of a binding site altering event for any of its motifs was deemed a variant adjacent TF.
We next sought to identify particular TFs that tend to be variant overlapping TFs at SLE allelic enVars. To this end, we calculated the fraction of times each TF motif has a binding site altering event (as defined above) at SLE allelic enVars. As background, we calculated the fraction of times each TF motif has a binding site altering event at non-allelic enVars. The significance of the difference between these two fractions was then calculated using a proportions test. Results are provided in Supplemental Data Set 15.
We used a similar procedure to identify particular TFs that tend to be variant adjacent TFs at SLE allelic enVars. We performed HOMER motif enrichment analysis using the full 170bp allelic enVar DNA sequences as input. The standard HOMER null model (scrambled input sequence, maintaining dinucleotide frequencies) was used as background. The fractions of motif "hits" obtained in the foreground vs. background set were then compared, and significance was again calculated using a proportions test. Results are provided in Supplemental Data Set 15.
Data availability
MPRA data are available in the Gene Expression Omnibus (GEO) database under accession number GSE143792. This dataset will remain private until the article is "in press". families are shown with padj <0.0001 and three or more allelic events at allelic enVar loci, or five or more predicted binding sites at allelic enVar loci, respectively. Il10  IFIH1  PXK  IL12A  DGKQ  BANK1   TNIP1   HLA   ATG5  OLIG3 -TNFAIP3   JAZF1  C7orf72 -IKZF1  GTF2IRD1 -GTF2I   IRF5 -TNPO3   TMEM39A -TIMMDC1   STAT4   1   0   20   40   60   80   140   130  100   2  3  4  5  6  7 -log (p) 10 Figure 5 
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